WO2006130527A3 - Mutations and polymorphisms of fibroblast growth factor receptor 1 - Google Patents

Mutations and polymorphisms of fibroblast growth factor receptor 1 Download PDF

Info

Publication number
WO2006130527A3
WO2006130527A3 PCT/US2006/020665 US2006020665W WO2006130527A3 WO 2006130527 A3 WO2006130527 A3 WO 2006130527A3 US 2006020665 W US2006020665 W US 2006020665W WO 2006130527 A3 WO2006130527 A3 WO 2006130527A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutations
fgfr1
polymorphisms
growth factor
factor receptor
Prior art date
Application number
PCT/US2006/020665
Other languages
French (fr)
Other versions
WO2006130527A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2006130527A2 publication Critical patent/WO2006130527A2/en
Publication of WO2006130527A3 publication Critical patent/WO2006130527A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G01N2333/501—Fibroblast growth factors [FGF] acidic FGF [aFGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G01N2333/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the epidermal growth factor receptor. The invention provides new FGFR1 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the FGFR1 mutations of the invention, expression vectors encoding the FGFR1 mutant polypeptides of the invention and organisms that express the FGFR1 mutant and polymorphic polynucleotides and/or FGFR1 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods that use the FGFR1 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2006/020665 2005-05-31 2006-03-30 Mutations and polymorphisms of fibroblast growth factor receptor 1 WO2006130527A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68595005P 2005-05-31 2005-05-31
US60/685,950 2005-05-31

Publications (2)

Publication Number Publication Date
WO2006130527A2 WO2006130527A2 (en) 2006-12-07
WO2006130527A3 true WO2006130527A3 (en) 2007-07-26

Family

ID=37482196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020665 WO2006130527A2 (en) 2005-05-31 2006-03-30 Mutations and polymorphisms of fibroblast growth factor receptor 1

Country Status (1)

Country Link
WO (1) WO2006130527A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188040B2 (en) 2009-05-05 2012-05-29 Amgen Inc. FGF21 mutants and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
UA105016C2 (en) 2008-10-10 2014-04-10 Амген Інк. Fgf21 mutants and uses thereof
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
CA2764835A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
EP2506861A1 (en) 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
JP2013523184A (en) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド Human FGF receptor and β-KLOTHO binding protein
CN102277414B (en) * 2010-06-10 2014-10-29 中国人民解放军军事医学科学院放射与辐射医学研究所 Method and kit for detecting polymorphism of region 1p36.22 associated to liver cell carcinogenesis and application thereof
BR112013026266A2 (en) * 2011-05-16 2020-11-10 Genentech, Inc treatment method, isolated and anti-fgfr1 antibodies, isolated nucleic acid, host cell, method of producing an antibody, pharmaceutical formulation, use of the antibody and method of treating diabetes in an individual

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021471A1 (en) * 1995-01-10 1996-07-18 Genta Incorporated Compositions and methods for treating tumor cells
US20030096241A1 (en) * 2001-03-22 2003-05-22 Zeria Pharmaceutical Co., Ltd. Method of testing squamous epithelial cells
WO2004050681A2 (en) * 2002-11-15 2004-06-17 Exelixis, Inc. Kinase modulators
EP1473043A1 (en) * 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021471A1 (en) * 1995-01-10 1996-07-18 Genta Incorporated Compositions and methods for treating tumor cells
US20030096241A1 (en) * 2001-03-22 2003-05-22 Zeria Pharmaceutical Co., Ltd. Method of testing squamous epithelial cells
WO2004050681A2 (en) * 2002-11-15 2004-06-17 Exelixis, Inc. Kinase modulators
EP1473043A1 (en) * 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 104, no. 11, Part 2, November 2004 (2004-11-01), 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 202B, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2004 (2004-11-01), KARAJANNIS MATTHIAS A ET AL: "Fibroblast growth factor receptor-1 expression and signaling in acute myeloid leukemia", XP002434275, Database accession no. PREV200510267128 *
RAND V ET AL: "Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 04 OCT 2005 UNITED STATES, vol. 102, no. 40, 4 October 2005 (2005-10-04), pages 14344 - 14349, XP002434258, ISSN: 0027-8424 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188040B2 (en) 2009-05-05 2012-05-29 Amgen Inc. FGF21 mutants and uses thereof
US8618053B2 (en) 2009-05-05 2013-12-31 Amgen Inc. FGF21 mutants multimers and uses thereof
US8795985B2 (en) 2009-05-05 2014-08-05 Amgen Inc. FGF 21 polypeptides comprising two or more mutations and uses thereof
US8835385B2 (en) 2009-05-05 2014-09-16 Amgen Inc. FGF21 polypeptides comprising two or more mutations and uses thereof

Also Published As

Publication number Publication date
WO2006130527A2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
Praschak-Rieder et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [11C] DASB positron emission tomography study
Kunugi et al. No association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder in a Japanese population: a multicenter study
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
ATE329610T1 (en) ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS
MX2009003562A (en) Elisa for vegf.
WO2006058306A3 (en) Medical hyperspectral imaging for evaluation of tissue and tumor
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
BRPI0520530A2 (en) method for predicting or monitoring a patient's response to an erbb receptor drug
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2006003414A3 (en) Biomarkers of alzheimer's disease
WO2007038073A3 (en) Mutations and polymorphisms of hdac11
WO2007058992A3 (en) Mutations and polymorphisms of hdac6
WO2007030454A3 (en) Mutations and polymorphisms of hdac9
WO2006076695A3 (en) Genetic screening for improving treatment of patients diagnosed with depression
WO2007109183A3 (en) Mutations and polymorphisms of fms-related tyrosine kinase 1
WO2007002217A3 (en) Mutations and polymorphisms of bcl-2
WO2007047998A3 (en) Mutations and polymorphisms of hdac2
WO2007053502A3 (en) Mutations and polymorphisms of hdac5
WO2007095032A3 (en) Mutations and polymorphisms of ptk2b
WO2007109515A3 (en) Mutations and polymorphisms of knockdown resistance polypeptide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06771436

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06771436

Country of ref document: EP

Kind code of ref document: A2